# Phase 1 Diabetes Mellitus trials recruiting: 79 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 79 trials in phase 1 for Diabetes Mellitus that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Diabetes Mellitus trials: 79 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/diabetes-mellitus

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 79
- Recruiting or not yet: 79
- Read on: November 19, 2026

## Trials

The 25 newest of 79, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07944118 | Examination of How the Duration of Fasting and Temporary Stopping of Zenagamtide Dosing Affect the Amount of Food Left in the Stomach in... | Novo Nordisk A/S | Phase 1 | Not yet recruiting | Overweight, Obesity, Type 2 Diabetes | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944118) |
| October 26, 2026 | NCT07896109 | A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes | Novo Nordisk A/S | Phase 1 | Recruiting | Diabetes Mellitus, Type 2 | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896109) |
| October 20, 2026 | NCT07881887 | A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2 Diabetes | Eli Lilly and Company | Phase 1 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 617 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881887) |
| October 15, 2026 | NCT07877038 | Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function | Chendu DIAO Pharmaceutical Group CO., LTD. | Phase 1 | Not yet recruiting | Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877038) |
| October 9, 2026 | NCT07868354 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New... | Novo Nordisk A/S | Phase 1 | Recruiting | Overweight, Obesity, Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868354) |
| October 2, 2026 | NCT07855133 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New... | Novo Nordisk A/S | Phase 1 | Recruiting | Overweight, Obesity, Type 2 Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855133) |
| September 25, 2026 | NCT07841860 | A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets in Healthy Participants With a Single Dose... | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Weight Management, Type 2 Diabetes | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841860) |
| September 9, 2026 | NCT07810309 | Metabolic Impact of Pancreatic Duct Decompression | Mayo Clinic | Phase 1 | Recruiting | Chronic Pancreatitis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07810309) |
| September 8, 2026 | NCT07807059 | A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment | Fujian Shengdi Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH), Type 2... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807059) |
| September 4, 2026 | NCT07803809 | Phase 1 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity | Shanghai Minwei Biotechnology Co., Ltd | Phase 1 | Recruiting | Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803809) |
| September 4, 2026 | NCT07803744 | A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity | Eli Lilly and Company | Phase 1 | Recruiting | Diabetes Mellitus, Type 1, Overweight, Obesity | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803744) |
| August 31, 2026 | NCT07794254 | A Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 2 Diabetes Mellitus | Hangzhou Reprogenix Bioscience, Inc | Phase 1 | Not yet recruiting | Diabete Mellitus, Diabete Type 2 | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07794254) |
| August 21, 2026 | NCT07778524 | Alpelisib Challenge Test (ACT) | Columbia University | Phase 1 | Recruiting | Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult Participants | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778524) |
| July 28, 2026 | NCT07730567 | A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B | Addpharma Inc. | Phase 1 | Not yet recruiting | Hyperlipidemia, Diabete Type 2 | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730567) |
| July 23, 2026 | NCT07723833 | A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants | AstraZeneca | Phase 1 | Recruiting | Healthy Participants | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723833) |
| July 2, 2026 | NCT07680673 | ENCRT-103-hPI: Evaluation of an Immune-protected ENCRT-103-hPI Containing Primary Human Islets in Adults With Type 1 Diabetes, With and... | Encellin | Phase 1 | Not yet recruiting | Type 1 Diabetes | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07680673) |
| June 30, 2026 | NCT07675590 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects | TIXiMED, Inc. | Phase 1 | Recruiting | Health Adult Subjects, Obesity & Overweight | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07675590) |
| June 9, 2026 | NCT07634770 | Bioavailability, Biopotency and Food Effect Study of SCD0503 Compared to Subcutaneous Regular Human Insulin | Sam Chun Dang Pharm. Co. Ltd. | Phase 1 | Recruiting | Diabetes Mellitus, Type 1 | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634770) |
| June 5, 2026 | NCT07630233 | A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy... | The United Bio-Technology (Hengqin) Co., Ltd. | Phase 1 | Recruiting | Type 2 Diabetes Mellitus (T2DM) | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630233) |
| June 2, 2026 | NCT07619820 | A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD) | CSL Behring | Phase 1 | Recruiting | End Stage Kidney Disease (ESKD) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619820) |
| May 27, 2026 | NCT07610213 | Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 Diabetes | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Type 1 Diabetes Mellitus (T1DM), Type 1 Diabetes Mellitus, Autoimmune Diabetes | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610213) |
| May 15, 2026 | NCT07590466 | A Study to Compare the Pharmacokinetics and Safety of the ATB-U101 and ATB-U1011+ATB-U1012 and ATB-1011+ATB-1012 in Healthy Caucasian... | Autotelicbio | Phase 1 | Not yet recruiting | Diabete Type 2, Hypertension | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07590466) |
| May 15, 2026 | NCT07590193 | A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus | Amgen | Phase 1 | Recruiting | Diabetes Mellitus, Type 2 | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07590193) |
| May 14, 2026 | NCT07588503 | FES Cycling With BFR in the Spinal Cord Injury Population | Sponsor not shown (see the record) | Phase 1 | Recruiting | Spinal Cord Injury, Cardio Vascular Disease, Metabolic Diseases, Type 2 Diabetes, Cardiovascular Disease | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07588503) |
| May 11, 2026 | NCT07578584 | A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and... | Novo Nordisk A/S | Phase 1 | Recruiting | Type 1 Diabetes (T1D), Overweight, Obesity, Healthy Volunteers | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07578584) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 8 |
| [Fujian Shengdi Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/fujian-shengdi-pharmaceutical-co-ltd) | 4 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 3 |
| The University of Texas Health Science Center at San Antonio | 3 |
| Hangzhou Reprogenix Bioscience, Inc | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| University of California, San Diego | 2 |
| [Boryung Pharmaceutical Co., Ltd](https://specstream.ai/data/clinical-trials/company/boryung-pharmaceutical-co-ltd) | 2 |
| [Jiangsu HengRui Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hengrui-medicine-co-ltd) | 2 |
| Columbia University | 2 |
| [Addpharma Inc.](https://specstream.ai/data/clinical-trials/company/addpharma-inc) | 2 |
| Biolexis Therapeutics | 1 |
| Rezubio Pharmaceuticals Co., Ltd. | 1 |
| [Gan & Lee Pharmaceuticals.](https://specstream.ai/data/clinical-trials/company/gan-and-lee-pharmaceuticals) | 1 |
| University of the Punjab | 1 |
| [Shanghai Minwei Biotechnology Co., Ltd](https://specstream.ai/data/clinical-trials/company/shanghai-minwei-biotechnology-co-ltd) | 1 |
| University of Maryland, Baltimore | 1 |
| Suzhou Siran Biotechnology Co.,Ltd. | 1 |
| AC Immune SA | 1 |
| Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. | 1 |
| AdipoPharma LLC | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |
| [Daewoong Pharmaceutical Co. LTD.](https://specstream.ai/data/clinical-trials/company/daewoong-pharmaceutical-co-ltd) | 1 |
| Immunocore Ltd | 1 |
| Nimble Science Ltd. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 31 |
| China | 14 |
| Germany | 8 |
| South Korea | 6 |
| Australia | 5 |
| Canada | 5 |
| Turkey (Türkiye) | 3 |
| Pakistan | 2 |
| Brazil | 2 |
| Spain | 2 |
| Netherlands | 1 |
| Chile | 1 |
| Georgia | 1 |
| Moldova | 1 |
| Romania | 1 |
| Serbia | 1 |
| South Africa | 1 |
| Ukraine | 1 |
| Singapore | 1 |
| Hungary | 1 |
| Poland | 1 |
| United Kingdom | 1 |
| Austria | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Building contractors in the United States](https://specstream.ai/data/businesses/building-contractors/united-states)
- [Specialty hospitals in the United States](https://specstream.ai/data/businesses/specialty-hospitals/united-states)
- [Laboratory equipment suppliers in the United States](https://specstream.ai/data/businesses/laboratory-equipment-suppliers/united-states)
- [Construction management firms in the United States](https://specstream.ai/data/businesses/construction-management-firms/united-states)
- [TV service providers in the United States](https://specstream.ai/data/businesses/tv-service-providers/united-states)
- [Motorcycle manufacturers in the United States](https://specstream.ai/data/businesses/motorcycle-manufacturers/united-states)
